PMID- 35305895
OWN - NLM
STAT- MEDLINE
DCOM- 20220330
LR  - 20220531
IS  - 0929-6646 (Print)
IS  - 0929-6646 (Electronic)
IS  - 0929-6646 (Linking)
VI  - 121
IP  - 4
DP  - 2022 Apr
TI  - Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination 
      compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
PG  - 766-777
LID - S0929-6646(22)00101-2 [pii]
LID - 10.1016/j.jfma.2022.02.020 [doi]
AB  - BACKGROUND/PURPOSE: Efficacy and safety data of heterologous prime-boost 
      vaccination against SARS-CoV-2 remains limited. METHODS: We recruited adult 
      volunteers for homologous or heterologous prime-boost vaccinations with 
      adenoviral (ChAdOx1, AstraZeneca) and/or mRNA (mRNA-1273, Moderna) vaccines. Four 
      groups of prime-boost vaccination schedules were designed: Group 1, 
      ChAdOx1/ChAdOx1 8 weeks apart; Group 2, ChAdOx1/mRNA-1273 8 weeks apart; Group 3, 
      ChAdOx1/mRNA-1273 4 weeks apart; and Group 4, mRNA-1273/mRNA-1273 4 weeks apart. 
      The primary outcome was serum anti-SARS-CoV-2 IgG titers and neutralizing 
      antibody titers against B.1.1.7 (alpha) and B.1.617.2 (delta) variants on day 28 
      after the second dose. Adverse events were recorded up until 84 days after the 
      second dose. RESULTS: We enrolled 399 participants with a median age of 41 years 
      and 75% were female. On day 28 after the second dose, the anti-SARS-CoV-2 IgG 
      titers of both heterologous vaccinations (Group 2 and Group 3) were significantly 
      higher than that of homologous ChAdOx1 vaccination (Group 1), and comparable with 
      homologous mRNA-1273 vaccination (Group 4). The heterologous vaccination group 
      had better neutralizing antibody responses against the alpha and delta variant as 
      compared to the homologous ChAdOx1 group. Most of the adverse events (AEs) were 
      mild and transient. AEs were less frequent when heterologous boosting was done at 
      8 weeks rather than at 4 weeks. CONCLUSION: Heterologous ChAdOx1/mRNA-1273 
      vaccination provided higher immunogenicity than homologous ChAdOx1 vaccination 
      and comparable immunogenicity with the homologous mRNA-1273 vaccination. Our 
      results support the safety and efficacy of heterologous prime-boost vaccination 
      using the ChAdOx1 and mRNA-1273 COVID-19 vaccines. (ClinicalTrials.gov number, 
      NCT05074368).
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Sheng, Wang-Huei
AU  - Sheng WH
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei 
      City, Taiwan; School of Medicine, National Taiwan University College of Medicine, 
      Taipei City, Taiwan.
FAU - Chang, Sui-Yuan
AU  - Chang SY
AD  - Department of Clinical Laboratory Sciences and Medical Biotechnology, National 
      Taiwan University College of Medicine, Taipei, Taiwan; Department of Laboratory 
      Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
FAU - Lin, Pin-Hung
AU  - Lin PH
AD  - Graduate Institute of Microbiology, College of Medicine, National Taiwan 
      University, Taipei, Taiwan.
FAU - Hsieh, Ming-Ju
AU  - Hsieh MJ
AD  - Department of Emergency Medicine, National Taiwan University Hospital, Taipei, 
      Taiwan; Occupational Safety and Health Office, National Taiwan University 
      Hospital, Taipei, Taiwan.
FAU - Chang, Hao-Hsiang
AU  - Chang HH
AD  - Department of Family Medicine, National Taiwan University Hospital and College of 
      Medicine, Taipei 10016, Taiwan.
FAU - Cheng, Chien-Yu
AU  - Cheng CY
AD  - Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health 
      and Welfare, Taoyuan, Taiwan; Institute of Public Health, School of Medicine 
      National Yang-Ming Chiao Tung University, Taiwan.
FAU - Yang, Hung-Chih
AU  - Yang HC
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei 
      City, Taiwan; Graduate Institute of Microbiology, College of Medicine, National 
      Taiwan University, Taipei, Taiwan.
FAU - Pan, Ching-Fu
AU  - Pan CF
AD  - Graduate Institute of Microbiology, College of Medicine, National Taiwan 
      University, Taipei, Taiwan.
FAU - Ieong, Si-Man
AU  - Ieong SM
AD  - Department of Clinical Laboratory Sciences and Medical Biotechnology, National 
      Taiwan University College of Medicine, Taipei, Taiwan.
FAU - Chao, Tai-Ling
AU  - Chao TL
AD  - Department of Clinical Laboratory Sciences and Medical Biotechnology, National 
      Taiwan University College of Medicine, Taipei, Taiwan; Genomics Research Center, 
      Academia Sinica, Taipei, Taiwan.
FAU - Chen, Jang-Pin
AU  - Chen JP
AD  - Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health 
      and Welfare, Taoyuan, Taiwan; School of Clinical Medicine, National Yang-Ming 
      Chiao Tung University, Taipei, Taiwan.
FAU - Cheng, Shu-Hsing
AU  - Cheng SH
AD  - Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health 
      and Welfare, Taoyuan, Taiwan; Institute of Public Health, School of Medicine 
      National Yang-Ming Chiao Tung University, School of Public Health, Taipei Medical 
      University, Taipei, Taiwan.
FAU - Chang, Shan-Chwen
AU  - Chang SC
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei 
      City, Taiwan; School of Medicine, National Taiwan University College of Medicine, 
      Taipei City, Taiwan. Electronic address: changsc@ntu.edu.tw.
LA  - eng
SI  - ClinicalTrials.gov/NCT05074368
PT  - Clinical Study
PT  - Journal Article
DEP - 20220316
PL  - Singapore
TA  - J Formos Med Assoc
JT  - Journal of the Formosan Medical Association = Taiwan yi zhi
JID - 9214933
RN  - 0 (COVID-19 Vaccines)
RN  - B5S3K2V0G8 (ChAdOx1 nCoV-19)
RN  - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273)
RN  - SARS-CoV-2 variants
SB  - IM
MH  - 2019-nCoV Vaccine mRNA-1273
MH  - Adult
MH  - *COVID-19/prevention & control
MH  - COVID-19 Vaccines/adverse effects
MH  - ChAdOx1 nCoV-19
MH  - Female
MH  - Humans
MH  - Immunity
MH  - *SARS-CoV-2
MH  - Vaccination
PMC - PMC8926322
OTO - NOTNLM
OT  - Adenovirus-vector vaccine
OT  - Coronavirus disease 2019 (COVID-19)
OT  - Immune response
OT  - Messenger RNA vaccine
OT  - Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)
COIS- Declaration of competing interest The authors have no conflicts of interest 
      relevant to this article.
EDAT- 2022/03/21 06:00
MHDA- 2022/03/31 06:00
PMCR- 2022/03/16
CRDT- 2022/03/20 20:26
PHST- 2022/02/04 00:00 [received]
PHST- 2022/02/24 00:00 [revised]
PHST- 2022/02/25 00:00 [accepted]
PHST- 2022/03/21 06:00 [pubmed]
PHST- 2022/03/31 06:00 [medline]
PHST- 2022/03/20 20:26 [entrez]
PHST- 2022/03/16 00:00 [pmc-release]
AID - S0929-6646(22)00101-2 [pii]
AID - 10.1016/j.jfma.2022.02.020 [doi]
PST - ppublish
SO  - J Formos Med Assoc. 2022 Apr;121(4):766-777. doi: 10.1016/j.jfma.2022.02.020. 
      Epub 2022 Mar 16.